Zealand Pharma A/S (ZLDPY)
| Market Cap | 3.05B -43.5% |
| Revenue (ttm) | 1.43B +16,519.7% |
| Net Income | 986.71M |
| EPS | 13.79 |
| Shares Out | n/a |
| PE Ratio | 3.09 |
| Forward PE | 18.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 210 |
| Open | 8.48 |
| Previous Close | n/a |
| Day's Range | 8.48 - 8.48 |
| 52-Week Range | 7.75 - 16.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
News
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on...
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am...
Zealand Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The event highlighted a shift in obesity drug development toward metabolic health, with survodutide and petrelintide showing promising profiles for liver fat reduction and tolerability. Flexible dosing and patient adherence are central, with major trials and pipeline expansion underway.
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side Effects
Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
Zealand Pharma lost a fifth of its market value on Monday after a late-stage trial found many patients stopped taking a weight-loss drug due to tolerability problems.
Zealand Pharma shares drop 20% as obesity drug side effects raise concerns
Zealand Pharma's shares fell more than 20% in early trade on Monday after trial data showed its obesity drug survodutide had worse side effects and higher patient dropout rates than riv...
Zealand Pharma Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted progress on the Metabolic Frontier 2030 strategy, with major clinical data for petrelintide and survodutide expected at ADA. Strong financial positioning, new research partnerships, and a focus on patient adherence and market expansion were emphasized.
Zealand Pharma Earnings Call Transcript: Q1 2026
Q1 2026 saw major clinical and financial milestones, including strong phase II and III results for obesity candidates, robust cash reserves, and the launch of a $200 million share buyback. Strategic partnerships and a focus on R&D underpin a positive outlook for 2026.
Zealand Pharma Quarterly report: Q1 2026
Zealand Pharma has published its Q1 2026 quarterly earnings report on May 7, 2026.
Zealand Pharma Slides: Q1 2026
Zealand Pharma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
Danish drug developer Zealand Pharma reported a smaller-than-expected first-quarter operating loss on Thursday, boosted by strong momentum in its obesity drug pipeline, and said it would l...
Zealand Pharma Slides: Corporate presentation
Zealand Pharma has posted slides in relation to its latest quarterly earnings report, which was published on March 17, 2026.
Zealand Pharma Transcript: Barclays 28th Annual Global Healthcare Conference
The discussion highlighted a robust pipeline targeting obesity and metabolic diseases, with Petrelintide showing strong efficacy and tolerability, and Survodutide poised for major phase III data this year. Strategic partnerships, financial strength, and upcoming clinical milestones position the company for significant growth.
Zealand Pharma Slides: Barclays 28th Annual Global Healthcare Conference
Zealand Pharma has posted slides in relation to its latest quarterly earnings report, which was published on March 11, 2026.
Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
Zealand Pharma obesity drug showed disappointing weight loss in a Phase 2 trial.
Zealand Pharma slump wipes billions off its value after obesity drug data disappoints
Shares in Zealand Pharma tumbled more than 30% on Friday, putting the Danish biotech firm on track for its worst trading day on record, after mid-stage trial results for obesity drug petrelintide fe...
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
Zealand Pharma Transcript: Study result
Petrelintide achieved sustained double-digit weight loss with a placebo-like safety profile in the phase II ZUPREME-1 trial, showing strong efficacy across doses and exceptional tolerability. These results support its advancement to phase III as a foundational therapy for chronic weight management.
Zealand Pharma Press release: Study result
Zealand Pharma issued a press release on March 5, 2026, disclosing material business information to investors.
Zealand Pharma Slides: Study result
Zealand Pharma has posted slides in relation to its latest quarterly earnings report, which was published on March 5, 2026.
Zealand Pharma Earnings Call Transcript: Q4 2025
2025 saw record revenue and profit, driven by the Roche partnership and strong R&D investment. Key obesity and metabolic assets, petrelintide and survodutide, are advancing with major clinical milestones expected in 2026, supported by a robust cash position.
Zealand Pharma Annual report: Q4 2025
Zealand Pharma has published its Q4 2025 annual report on February 19, 2026.
Zealand Pharma Slides: Q4 2025
Zealand Pharma has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 19, 2026.
Zealand Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference
Ambitious plans target obesity and metabolic diseases, with major clinical milestones for petrelintide and Survodutide expected in 2024. Strategic partnerships with Roche and Boehringer Ingelheim support a robust pipeline, aiming for five product launches in five years and significant investment in research.
Zealand Pharma Transcript: CMD 2025
Ambitious plans target redefining obesity management with petrelintide as a foundational therapy, a fivefold increase in research investment, and five launches by 2030. Strategic partnerships, robust clinical programs, and a focus on patient experience and tolerability underpin the vision to become a generational biotech.